MinorProton pump inhibitors×Reversible P2Y12 receptor inhibitor
Updated · Methodology
Mechanism
Ticagrelor acts directly on the P2Y12 receptor and needs no CYP2C19 activation, so the classic clopidogrel-omeprazole problem does not carry over to this pair. The ticagrelor label focuses its warnings on bleeding risk and on aspirin maintenance doses, not on proton pump inhibitors.
Symptoms
No symptoms attributable to the pairing. Ticagrelor's own continue: bruising, gum or nose bleeding, dyspnoea appearing in the first weeks and usually mild. Black stools or coffee-ground vomit remain alarm signs.
Management
Omeprazole can stay alongside ticagrelor when there is a gastric indication. What does not change is bleeding surveillance and the rule against stopping the antiplatelet on your own, since early withdrawal raises cardiovascular risk.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Omeprazol Normon 10 mg cápsulas duras gastrorresistentes EFG (2026)– AEMPS, CIMA, nº registro 69233, sección 4.5
- AEMPS: Ficha técnica Ticagrelor Cinfa 90 mg comprimidos recubiertos con película EFG (2025)– AEMPS, CIMA, nº registro 89558, secciones 4.4 y 4.5